Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Mary-Ellen Taplin

Dana–Farber Cancer Institute, Boston

Martin Gleave

Vancouver Prostate Centre

Neal D. Shore

START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC

Angela Lopez-Gitlitz

Johnson & Johnson, Los Angeles

Alexander Kretschmer

Johnson & Johnson, Spring House, PA

Eleni Efstathiou

Knight Cancer Institute, Oregon Health and Science University, Portland

Paul L. Nguyen

Mass General Brigham, Boston

Ronaldo Damião

Universidade do Estado do Rio de Janeiro, Rio de Janeiro

Toshiyuki Kamoto

University of Miyazaki, Miyazaki City, Japan

Ashley Ross

Northwestern University Feinberg School of Medicine, Chicago

Alberto Briganti

Urological Research Institute, Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan

Boris A. Hadaschik

University of Duisburg-Essen, Essen, Germany

Axel Heidenreich

Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital of Cologne, Cologne, Germany

Álvaro Juárez Soto

Hospital Universitario de Jerez de la Frontera, Cadiz, Spain

Huihui Ye

Geoffrey Gotto

University of Calgary, Calgary, AB, Canada

Brendan Rooney

Johnson & Johnson, High Wycombe, United Kingdom

Shaozhou Ken Tian

Johnson & Johnson, Spring House, PA

Lisa Wetherhold

Johnson & Johnson, Spring House, PA

Branko Miladinovic

Johnson & Johnson, San Diego, CA

Sharon A. McCarthy

Johnson & Johnson, Spring House, PA

Christopher P. Evans

University of Nevada, Reno

Adam S. Kibel

Mass General Brigham, Boston